OBJECTIVE: To assess the morbidity after sentinel lymph node (SLN) biopsy compared with SLN and completion level I and II axillary lymph node dissection (ALND) in a prospective multicenter study. SUMMARY BACKGROUND DATA: ALND after breast cancer surgery is associated with considerable morbidity. We hypothesized: 1) that the morbidity in patients undergoing SLN biopsy only is significantly lower compared with those after SLN and completion ALND level I and II; and 2) that SLN biopsy can be performed with similar intermediate term morbidity in academic and nonacademic centers. METHODS: Patients with early stage breast cancer (pT1 and pT2 <or= 3 cm, cN0) were included between January 2000 and December 2003 in this prospective Swiss multicenter study. All patients underwent SLN biopsy. In all patients with SLN macrometastases and most patients with SLN micrometastases (43 of 68) or isolated tumor cells (11 of 19), a completion ALND was performed. Postoperative morbidity was assessed based on a standardized protocol. RESULTS: SLN biopsy alone was performed in 449 patients, whereas 210 patients underwent SLN and completion ALND. The median follow-ups were 31.0 and 29.5 months for the SLN and SLN and completion ALND groups, respectively. Intermediate-term follow-up information was available from 635 of 659 patients (96.4%) of enrolled patients. The following results were found in the SLN versus SLN and completion ALND group: presence of lymphedema (3.5% vs. 19.1%, P < 0.0001), impaired shoulder range of motion (3.5% vs. 11.3%, P < 0.0001), shoulder/arm pain (8.1% vs. 21.1%, P < 0.0001), and numbness (10.9% vs. 37.7%, P < 0.0001). No significant differences regarding postoperative morbidity after SLN biopsy were noticed between academic and nonacademic hospitals (P = 0.921). CONCLUSIONS: The morbidity after SLN biopsy alone is not negligible but significantly lower compared with level I and II ALND. SLN biopsy can be performed with similar short- and intermediate-term morbidity in academic and nonacademic centers.
OBJECTIVE: To assess the morbidity after sentinel lymph node (SLN) biopsy compared with SLN and completion level I and II axillary lymph node dissection (ALND) in a prospective multicenter study. SUMMARY BACKGROUND DATA: ALND after breast cancer surgery is associated with considerable morbidity. We hypothesized: 1) that the morbidity in patients undergoing SLN biopsy only is significantly lower compared with those after SLN and completion ALND level I and II; and 2) that SLN biopsy can be performed with similar intermediate term morbidity in academic and nonacademic centers. METHODS:Patients with early stage breast cancer (pT1 and pT2 <or= 3 cm, cN0) were included between January 2000 and December 2003 in this prospective Swiss multicenter study. All patients underwent SLN biopsy. In all patients with SLN macrometastases and most patients with SLN micrometastases (43 of 68) or isolated tumor cells (11 of 19), a completion ALND was performed. Postoperative morbidity was assessed based on a standardized protocol. RESULTS: SLN biopsy alone was performed in 449 patients, whereas 210 patients underwent SLN and completion ALND. The median follow-ups were 31.0 and 29.5 months for the SLN and SLN and completion ALND groups, respectively. Intermediate-term follow-up information was available from 635 of 659 patients (96.4%) of enrolled patients. The following results were found in the SLN versus SLN and completion ALND group: presence of lymphedema (3.5% vs. 19.1%, P < 0.0001), impaired shoulder range of motion (3.5% vs. 11.3%, P < 0.0001), shoulder/arm pain (8.1% vs. 21.1%, P < 0.0001), and numbness (10.9% vs. 37.7%, P < 0.0001). No significant differences regarding postoperative morbidity after SLN biopsy were noticed between academic and nonacademic hospitals (P = 0.921). CONCLUSIONS: The morbidity after SLN biopsy alone is not negligible but significantly lower compared with level I and II ALND. SLN biopsy can be performed with similar short- and intermediate-term morbidity in academic and nonacademic centers.
Authors: A Haid; T Kuehn; P Konstantiniuk; R Köberle-Wührer; M Knauer; R Kreienberg; G Zimmermann Journal: Eur J Surg Oncol Date: 2002-11 Impact factor: 4.424
Authors: M P Schijven; A J J M Vingerhoets; H J T Rutten; G A P Nieuwenhuijzen; R M H Roumen; M E van Bussel; A C Voogd Journal: Eur J Surg Oncol Date: 2003-05 Impact factor: 4.424
Authors: Keiva L Bland; Rebecca Perczyk; Wei Du; Christine Rymal; Prathima Koppolu; Ruthie McCrary; Kathryn A Carolin; Mary Ann Kosir Journal: Am J Surg Date: 2003-11 Impact factor: 2.565
Authors: Umberto Veronesi; Giovanni Paganelli; Giuseppe Viale; Alberto Luini; Stefano Zurrida; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Chris Robertson; Patrick Maisonneuve; Giuseppe Renne; Concetta De Cicco; Francesca De Lucia; Roberto Gennari Journal: N Engl J Med Date: 2003-08-07 Impact factor: 91.245
Authors: Christopher A Tokin; Frederick O Cope; Wendy L Metz; Michael S Blue; Beth M Potter; Bonnie C Abbruzzese; Richard D Hartman; Marcus T Joy; Dennis W King; Lori A Christman; David R Vera; Anne M Wallace Journal: Clin Exp Metastasis Date: 2012-06-23 Impact factor: 5.150
Authors: Hannes J Larusson; Urs von Holzen; Carsten T Viehl; Farid Rezaeian; Hans-Martin Riehle; Daniel Oertli; Ulrich Guller; Markus Zuber Journal: Int J Colorectal Dis Date: 2014-04-25 Impact factor: 2.571
Authors: Stephanie R Land; Jacek A Kopec; Thomas B Julian; Ann M Brown; Stewart J Anderson; David N Krag; Nicholas J Christian; Joseph P Costantino; Norman Wolmark; Patricia A Ganz Journal: J Clin Oncol Date: 2010-08-02 Impact factor: 44.544
Authors: Benjamin Weixler; Andreas Rickenbacher; Dimitri Aristotle Raptis; Carsten T Viehl; Ulrich Guller; Jessica Rueff; Andreas Zettl; Markus Zuber Journal: World J Surg Date: 2017-09 Impact factor: 3.352
Authors: Igor Langer; Ulrich Guller; Carsten T Viehl; Holger Moch; Edward Wight; Felix Harder; Daniel Oertli; Markus Zuber Journal: Indian J Surg Oncol Date: 2010-08-07
Authors: Jan J Kootstra; Josette E H M Hoekstra-Weebers; Johan S Rietman; Jakob de Vries; Peter C Baas; Jan H B Geertzen; Harald J Hoekstra Journal: Ann Surg Oncol Date: 2010-03-11 Impact factor: 5.344
Authors: Mei R Fu; Yvette P Conley; Deborah Axelrod; Amber A Guth; Gary Yu; Jason Fletcher; David Zagzag Journal: Breast Date: 2016-07-22 Impact factor: 4.380